Astrea Bioseparations expands manufacturing and warehousing in North America

  • New 12,000 sq. ft. facility in Massachusetts will increase capacity for pre-packed column products and services and create up to 15 new full-time positions.


Astrea Bioseparations (“Astrea Bio”), a leading provider of high-quality bioseparation and purification technologies that help to improve patient outcomes with safer and more effective production of therapeutics, announces the expansion of its manufacturing and warehousing capabilities in the US. The increased capacity reflects growing demand for the Company’s chromatography solutions in North American markets.

The new ~12,000 sq. ft. facility allows Astrea Bio to bring its innovative products to customers within record lead times of 3-5 weeks for off-the-shelf products, and 6-8 weeks for large-scale resin orders. The site expands the Company’s US footprint by over fourfold, supporting its continued growth trajectory as it also increases its workforce by up to 9% over an 18-month period.

Completing in Q4 2023, the facility, located in Canton, Massachusetts, will provide significantly increased manufacturing and warehousing capacity. Hosting a variety of workspaces, including cleanroom laboratories for column packing services, offices, warehousing, and column assembly spaces, the facility will provide a vital hub to Astrea Bio’s North American supply network, as well as locally available technical expertise and customer support.

Dedicated column packing cleanrooms will increase production capacity for pre-packed column products and services. Increased warehousing space will be available for all products, including the Company’s broad range of affinity, hydrophobic interaction chromatography and ion exchange adsorbents and resins for commercial-scale biologic production, and its AstreAdept® range of nanofiber-based purification technology for efficient production of cell and gene therapies.

Astrea Bio operates a global network of offices and manufacturing facilities, to ensure reliable supply of high-quality products. The Company’s 170 employees are located at its Cambridge, UK headquarters, manufacturing facilities in Gloucestershire, UK, the Isle of Man, Joliette, Canada and Canton, MA, alongside additional office facilities in Singapore.

Expanding our presence in the US reflects growing demand for our chromatography products and services to support effective development and production of cutting-edge biologics, including cell and gene therapies,” commented Chris Brown, Operations Director at Astrea Bioseparations. “The new site gives us greater capacity to support new and existing customers by providing innovative and high-quality products, within market-leading timeframes, as well as offering local technical expertise.”

 

More news and updates 

DLRC achieves King’s Award for Enterprise in International Trade

DLRC Ltd has been honoured with the King’s Award for Enterprise, recognising its outstanding performance in international trade. This places DLRC among a select group of only 252 organisations in the UK to receive this prestigious award.

Optibrium partners with FMC Corporation to transform agrochemical discovery

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.

Touchlight Genetics and NPL awarded grant to develop novel gene-length single-stranded genome editing template

Touchlight Genetics, in partnership with the National Physical Laboratory (NPL) have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines Manufacture, Round 2 call. 

PrecisionLife and Metrodora Institute launch clinical trials to accelerate treatment of ME/CFS and long Covid patients

Up to 1,000 patients being recruited into targeted precision medicine clinical trials expected to readout results as early as this year; trials are designed to provide validation of safety and effectiveness for novel diagnostics and innovative clinical care pathways in ME/CFS and Long Covid.

European Life Sciences sector primed for growth in 2024 driving real estate demand and investment opportunities

The European Life Science sector has been marked by strong growth and resilience in recent years and is set for significant expansion in 2024, driven by new medical treatments and both private and public funding according to JLL’s Life Sciences Industry & Real Estate Perspective report.

Ingenza expanding codABLE® gene design algorithm to aid recombinant protein production in yeast

Scottish CRDMO Ingenza has secured innovation funding to adapt its codABLE® machine learning platform to precisely control recombinant protein expression in the industrial yeast Pichia pastoris. This game-changing project will accelerate the development of therapeutics, enzymes and other proteins by harnessing machine learning to fine-tune codon usage, ensuring seamless compatibility with the production host and maximising production yields.

Arecor and Medtronic Diabetes establish collaboration to develop novel thermostable insulin for implantable pump delivery

Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump

Infinitopes secures £12.8 million seed financing to enhance its Precision ImmunomicsTM antigen discovery technologies

Infinitopes Precision Immunomics, an integrated cancer biotech combining world-leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8 million seed funding round led by Octopus Ventures.

Business Opportunity: Advance your workforce with a Bioscience Degree Apprenticeship

Manchester Metropolitan University have opened applications for the Laboratory Science Degree Apprenticeships in Bioscience. New cohorts are set to begin in September.

Poolbeg Pharma plc announces exclusive option agreement to acquire Orphan Drug Candidate for Behçet's Disease

Poolbeg Pharma plc announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patient's suffering from Behçet's Disease.

 

More within